Press Releases

We’re Delivering the Promise of Healthier Lives.

CURE PHARMACEUTICAL 

Press Releases

We specialize in optimal formulations to achieve targeted release and exposure of medications.​

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

OXNARD, Calif., July 11, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the […]

read more

CURE Pharmaceutical to Present on the Increased Bioavailability for Cannabinoids Due to New Delivery Technologies at O’Cannabiz Conference

LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that CEO Rob Davidson will be presenting at the O’Cannabiz Conference & Expo on June 9 at 2:50 PM ET in Toronto, Canada. Davidson will discuss “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing […]

read more
CURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery Production

CURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery Production

OXNARD, Calif. –  May 1, 2018 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it received an investment of $500,000 from a strategic partner to advance its cannabinoid-based drug delivery product line. This investment comes from a pharmaceutical partner in the form of a convertible loan. “This is an important […]

read more
CURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid Molecules

CURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid Molecules

LOS ANGELES, April 04, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the acquisition of two patents that ensure CURE has a competitive advantage in the extraction and purification of Cannabis plant material, as well as subsequent processing of Cannabis extracts for drug formulation. “The endocannabinoid system is a […]

read more
CURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of Year

CURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of Year

OXNARD, Calif., April 03, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery company, today reported the company’s Q1 2018 accomplishments. The company strengthened its leadership team with biopharmaceutical expertise, secured additional financing, and boosted nutraceutical product distribution, while advancing towards the launch of its first pharmaceutical CUREfilm™ product. “We see solid growth this quarter […]

read more
CURE Pharmaceutical Announces Closing of $1 Million Bridge Financing and Prepares to Uplist to NASDAQ

CURE Pharmaceutical Announces Closing of $1 Million Bridge Financing and Prepares to Uplist to NASDAQ

OXNARD, Calif. – March 22, 2018 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it secured a $1 million bridge financing from accredited investors for working capital and the potential uplisting to NASDAQ. Alexander Capital, LP acted as the sole placement agent for the transaction. “This capital raise takes […]

read more

CURE Pharmaceutical to Participate in Hawaiian Cannabis Science Dinner & Dialogue Panel to Discuss Company’s Research on the Endocannabinoid System for Breakthrough Therapies

LOS ANGELES – March 23, 2018 – CURE Pharmaceutical (“CURE” or the “Company”) (OTC: CURR), an innovative drug delivery and development company, today announced that the Company will participate in an educational panel about cannabis science in Hawaii. This “Dinner & Dialogue” is put on by Lua Ola, Hawaii’s leading medical cannabis provider, and will address […]

read more
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing

Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing

LOS ANGELES–(GlobeNewswire)— CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today named Steven Ruhl Vice President of Manufacturing. Bringing more than 35 years of experience, Ruhl will oversee all process development and manufacturing operations “Steven has a proven track record of building and developing high performing teams within the biopharmaceutical industry,” said […]

read more
CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting

CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting

OXNARD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced Gene Salkind, M.D. joined the company’s Advisory Board and also became the first investor of larger financing that will lead CURE to an application with the national securities exchange within the first quarter. Dr. Salkind […]

read more
CURE Pharmaceutical Adds New VP of Strategy and Business Development

CURE Pharmaceutical Adds New VP of Strategy and Business Development

LOS ANGELES–(BUSINESS WIRE)–CURE Pharmaceutical (OTCQB: CURR) (“CURE”), an innovative drug delivery and development company, today named Dr. Vered Gigi, Vice President of Strategy and Business Development. Dr. Gigi will oversee CURE’s strategy to deliver sustained growth and diversified revenue. “We are starting a pivotal year for CURE, focusing on both established and new strategic partnerships that […]

read more
CURE Pharmaceutical to Present at 2018 Biotech Showcase

CURE Pharmaceutical to Present at 2018 Biotech Showcase

OXNARD, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, will be a presenting company at the 2018 Biotech Showcase in San Francisco, CA, taking place January 8 -10, 2018. “We look forward to sharing how CURE can improve the delivery of pharmaceuticals to improve patient outcomes and save money,” […]

read more
CURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication Delivery

CURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication Delivery

OXNARD, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced the launch of their new brand initiative, inspired by the company’s mission to support patient needs for better delivery of medication. “Our new branding offers an opportunity to elevate awareness around the challenges patients experience with traditional […]

read more

Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders

CURE to Manufacture Therapix Proprietary Entourage Formulation (Dronabinol and PEA)-Based Product Using Proprietary CureFilm™ Technology OXNARD, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) — Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology announced today that it has entered into a product development agreement with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company […]

read more
CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis

CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis

OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its subsidiary company, Oak Therapeutics, has completed a critical milestone of its Phase I Small Business Innovative Research Contract (SBIR) from the National Institutes of Health/National Institute of Allergy and Infectious Diseases  (NIH/ NIAID) to […]

read more

CURE Pharmaceutical Launches New Academic Partnership Program Providing the Company’s Proprietary CureFilm™ for More Humane and Effective Animal Research

OXNARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced the launch of a new academic partnership program, CureDotsTM. Under the CureDotsTM program, academic institutions may access the Company’s patented, multilayer oral thin film (OTF), CureFilm Oral™, for more humane and effective animal research and testing. CureDotsTM are punch-hole dot […]

read more

CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfunction Drug Using Company’s Proprietary Curefilm™ Into Asian Market

OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, today announced that it has partnered with a leading pharmaceutical distribution company to deliver a generic erectile dysfunction (ED) drug on its patented, multilayer oral thin film (OTF), CureFilm™, into the Asian market. […]

read more
CURE Pharmaceutical Appoints CannaKids CEO and Cannabis Cancer Advocate Tracy Ryan to Advisory Board

CURE Pharmaceutical Appoints CannaKids CEO and Cannabis Cancer Advocate Tracy Ryan to Advisory Board

OXNARD, Calif., June 27, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today the appointment of CannaKids Founder and CEO Tracy Ryan to its advisory board. Ryan founded CannaKids, a California Cooperative Cooperation that specializes in the creation of lab tested and Ph.D. scientist extracted cannabis […]

read more

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (Nasdaq:TRPX), (“Therapix”), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, announced today that they signed a memorandum […]

read more
Getting Healthy, Not High: Using Cannabis to Fight Cancer

Getting Healthy, Not High: Using Cannabis to Fight Cancer

“Fighting cancer. Cure Pharmaceuticals, along with its partner, the Technion-Israel Institute of Technology, will be researching cannabinoid compounds in the treatment leukemia and prostate cancer. Accumulating evidence suggests that cannabinoids possess certain anti-tumor qualities. Various studies have demonstrated the effectiveness of cannabinoids for regressing different cancer types. There are also numerous cases of cannabis helping children suffering from rare […]

read more

Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market

OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, is commenting today on a new research report by Transparency Market Research (TMR) that predicts the global thin film drug manufacturing market to be worth US $15.9 billion by the end […]

read more

Cure Pharma’s API Delivery Tech on the Tip of the Tongue

In-Pharmatechnologist covered CURE’s newest patent filing and the potential of this new technology. Cure Pharmaceutical has submitted a patent application for an oral film delivery technology it says can combine several active pharmaceutical ingredients without negative interaction. The patent application, titled ‘Pharmaceutical Composition with Ionically Crosslinked Polymer Encapsulation of Active Ingredient’ (US20170100327), covers the proprietary […]

read more
CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion-Israel Institute of Technology on Cancer-Fighting Cannabinoids

CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion-Israel Institute of Technology on Cancer-Fighting Cannabinoids

OXNARD, Calif., May 31, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical  (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that the CURE and the CannaKids partnership has entered into a strategic research collaboration with Technion Research and Development Foundation Ltd., wholly owned subsidiary of the Technion-Israel Institute of […]

read more
CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD

CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD

OXNARD, Calif., May 24, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received their first purchase order from their recently announced agreement with diverse international pharmaceutical company Meroven Ltd. for the development of oral thin film (OTF) delivery for several molecules, including […]

read more